For Healthcare Professionals

Analysis of Specimens From Individuals With Pulmonary Fibrosis


About the study

The etiology of pulmonary fibrosis is unknown. Analyses of blood, genomic DNA, and specimens procured by bronchoscopy, lung biopsy, lung transplantation, clinically-indicated extra-pulmonary biopsies, or post-mortem examination from individuals with this disorder may contribute to our understanding of the pathogenic mechanisms of pulmonary fibrosis. The purpose of this protocol is to procure and analyze blood, genomic DNA, and specimens by bronchoscopy, lung biopsy, lung transplantation, extra-pulmonary biopsies, or post-mortem examination from subjects with pulmonary fibrosis. In addition, blood, genomic DNA, clinically-indicated extra-pulmonary biopsies, as well as bronchoscopy and post-mortem examination specimens may be procured and analyzed from relatives of subjects with hereditary forms of pulmonary fibrosis; blood, genomic DNA, and bronchoscopy specimens may be procured from healthy research volunteers....

Who can take part

You may be eligible to participate in the study if you meet the following criteria:



Individuals who are 18 years of age or older with any of the following:

  1. Idiopathic pulmonary fibrosis [defined by the American Thoracic Society/European Respiratory Society guidelines],
  2. Familial pulmonary fibrosis [defined as idiopathic pulmonary fibrosis in two or more first-degree relatives],
  3. Relatives of patients with hereditary pulmonary fibrosis,
  4. Hermansky-Pudlak syndrome (diagnosed by paucity or deficiency of platelet dense bodies on whole mount electron microscopy or by genetic testing),
  5. Pulmonary fibrosis associated with collagen vascular diseases or autoinflammatory disorders,
  6. Pulmonary fibrosis post-COVID-19 [i.e., pulmonary fibrosis in an individual recovering from SARS-CoV-2 infection], or
  7. Healthy research volunteers by history and indicated tests (individuals without history of chronic pulmonary disorder, collagen vascular disease, or bleeding disorder).



Individuals with any of the following:

  1. Significant inhalational exposure to fibrogenic fibers or dusts or exposure to drugs associated with pulmonary fibrosis,
  2. Uncontrolled ischemic heart disease,
  3. Uncorrectable bleeding diathesis,
  4. Pregnancy or lactation (excluded due to exposure of unnecessary risks), or
  5. Inability to give informed consent (excluded due to exposure of unnecessary risks).
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Pulmonary Fibrosis,Healthy Volunteers,Hermansky-Pudlak Syndrome (HPS)

Age (in years)

18 - 115

Participants needed


Treatment type



National Institutes of Health Clinical Center (CC) identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.